Press Release: Phase 2 data published in NEJM show potential

Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MSHigh-dose frexalimab significantly reduced dis...

Related Keywords

Paris , France General , France , Felix Lauscher , Nathalie Pham , Eva Schaefer Jansen , Corentine Driancourt , Sally Bain , Timothy Gilbert , Sandrine Guendoul , Tarik Elgoutni , Patrick Vermersch , Euronext , Consortium Of Multiple Sclerosis Centers , Immunext Inc , Nasdaq , University Of Lille , New England Journal , Multiple Sclerosis Centers , Multiple Sclerosis Impact Scale , Multiple Sclerosis , Systemic Lupus Erythematosus , Private Securities Litigation Reform Act , Statement Regarding Forward Looking ,